A lab compound called PFI-3 may help stabilize artery plaque, according to research reviewed by Gram. In a 2026 mouse study, treated animals on high-fat diets had smaller plaques, smaller dead-tissue cores, and fewer inflammatory immune cells, with blood cholesterol unchanged. Effects in people remain untested.

According to research reviewed by Gram, a lab compound called PFI-3 may help make artery plaque more stable. Plaque is the fatty buildup that can narrow arteries and lead to heart attacks. Scientists fed mice a high-fat diet and then gave some of them PFI-3 by mouth. The treated mice had smaller plaques, smaller dead-tissue centers inside those plaques, and fewer immune cells crowding into their artery walls. Their plaques also contained more collagen, a protein that helps hold plaque together. Blood fat levels did not change, which suggests the compound works on the artery wall itself. In lab dishes, the team also traced a chain of signals in artery muscle cells that makes it harder for the body to clean up dead cells. Blocking the first signal in that chain helped cells clean up more effectively. These results come from mice and cells, so they do not show that PFI-3 is safe or helpful for people.

Key Statistics

A 2026 mouse study found that the compound PFI-3 reduced artery plaque area, dead-tissue core size, and immune cell buildup in high-fat-diet-fed ApoE-deficient mice, without changing their blood cholesterol levels.

A 2026 laboratory study identified a four-step chain of molecular signals, running from the protein BRG1 to the “don’t eat me” marker CD47, that impairs how mouse artery muscle cells are cleared by immune cells during inflammation.

A 2026 study in mice and cultured cells showed that restoring the small regulatory molecule miR-193b-3p with PFI-3 reversed the increase in CD47 that inflammation caused in artery muscle cells.

The Quick Take

  • What they studied: Can a compound called PFI-3 make artery plaque less dangerous, and how does it affect the cells that clear dead material from artery walls?
  • Who participated: Mice bred to develop artery plaque (ApoE-deficient mice) that were fed a high-fat diet, plus mouse artery muscle cells grown in lab dishes. The exact number of animals and cell experiments was not listed in the summary provided.
  • Key finding: Mice given PFI-3 had smaller artery plaques, smaller dead-tissue cores, and fewer immune cells in their artery walls than untreated mice. Their blood cholesterol and fat levels did not change, so the effect appears to come from the artery wall rather than from lower blood fats.
  • What it means for you: This is early laboratory and animal research. It does not mean that people should take PFI-3 or any similar compound. It does suggest that the artery wall itself may be a useful target for future heart disease treatments, which doctors and researchers will need to test carefully in people.

The Research Details

The researchers used two main approaches. First, they fed mice a high-fat diet to encourage plaque buildup in their arteries. Some mice received PFI-3 by mouth, while others received a plain liquid with no active ingredient, called a vehicle. At the end of the study, the team examined the arteries under a microscope to measure plaque size, what the plaque was made of, how many immune cells were inside it, and how well immune cells were removing dead cells.

Second, they worked with mouse artery muscle cells grown in lab dishes. They exposed these cells to a substance that triggers inflammation, similar to a bacterial infection. Then they either reduced a protein called BRG1 using genetic tools or treated the cells with PFI-3. They measured how well immune cells, called macrophages, could engulf and clear dead cells that the muscle cells had been exposed to.

Finally, the team mapped the chain of molecular signals that connected these steps. They checked which genes BRG1 switched on, which signals those genes sent, and whether restoring one of those signals reversed the effects. This type of step-by-step testing helps show cause and effect, not just a connection.

Combining whole-animal experiments with lab-dish experiments is useful because it lets scientists see both the big picture and the exact mechanism. The mouse experiments show whether a treatment changes plaque in a living body. The cell experiments show how it works, step by step. When both approaches point the same way, the finding is more believable than either approach alone.

The study used a controlled design, with a comparison group receiving a vehicle and detailed tests of the proposed mechanism. These are strengths. However, the summary provided does not list the number of mice or the number of repeated experiments, so it is hard to judge how much variation there was. The paper is also a single study, and results from one lab usually need to be repeated by others before they are widely accepted. Because the work was published in a peer-reviewed journal, it has passed expert review, but that review does not guarantee that every result will hold up.

What the Results Show

The main result was that PFI-3 reduced several signs of unstable artery plaque in mice. Plaques were smaller, the dead-tissue centers inside them (called necrotic cores) were smaller, and fewer inflammatory immune cells had moved into the artery walls. At the same time, the plaques contained more collagen and more alpha-smooth muscle actin, both of which are associated with a sturdier plaque cap that is less likely to break open. Plaques that break open can cause blood clots, which is how many heart attacks and strokes begin.

An important detail is that PFI-3 did not change circulating lipids, meaning the amount of fat and cholesterol in the blood. Many heart disease treatments work mainly by lowering blood cholesterol. The fact that this compound seemed to help without changing blood fats suggests that it may act directly on the artery wall. This is a key reason why the researchers focused on the cells in the artery wall.

The team also looked at how the body clears dead cells from plaque. When dead cells build up and are not cleaned up, they can add to inflammation and plaque instability. In the mice treated with PFI-3, fewer free dead cells were found in the artery, and more of them were cleared by immune cells. This suggests that the compound helped the body’s cleanup crew do its job better.

In the lab, the researchers found that inflammation increased BRG1, a protein that controls which genes are switched on. Higher BRG1 led to higher levels of a protein called SLUG, which lowered a small regulatory molecule called miR-193b-3p. Lower miR-193b-3p allowed more of a surface marker called CD47 to be made. CD47 works like a “don’t eat me” signal, telling immune cells to leave cells alone. Reducing BRG1 lowered CD47 and improved clearing of dead cells. PFI-3 produced the same pattern, restoring the regulatory molecule and lowering CD47.

The researchers found that BRG1 sits directly on the gene region that controls SLUG, which is how it turns SLUG on. They also showed that restoring miR-193b-3p was enough to reverse the effect on CD47, which supports the idea that this chain of steps truly matters. These details make the proposed mechanism more convincing, although they still come from cell experiments rather than human tissue.

The study also notes that PFI-3 blocks not only BRG1 but also two related proteins, BRM and PBRM1. The authors state that these related proteins may also have contributed to the results and that they cannot rule this out. This means the exact target responsible for the benefit is not yet fully confirmed.

Previous research has shown that inflammation drives artery plaque instability and that the “don’t eat me” signal CD47 is found at high levels in plaques. This study adds a new piece to that picture by linking CD47 to a specific chain of control genes and identifying BRG1 as a potential upstream switch. It also fits with a broader idea in heart research: that making plaques more stable and helping the body clear dead cells may be as important as simply lowering cholesterol. The study does not overturn existing knowledge, but it points to a new potential target that researchers had not previously tested in this way.

The most important limitation is that the study was done in mice and in cells grown in lab dishes. Mice and humans differ in many ways, and treatments that work in animals often fail in people. The study also did not test whether PFI-3 is safe over long periods, and it did not test whether it prevents heart attacks or strokes. Plaque measurements show changes in the artery, but they do not directly measure whether patients would have fewer cardiac events.

Another limitation is that PFI-3 affects more than one protein family member. The researchers acknowledge that inhibiting BRM and PBRM1 may have contributed to the results. This makes it harder to say exactly which target is responsible. The summary does not list sample sizes or statistical details, so readers should look for those in the full paper before drawing firm conclusions.

The Bottom Line

At this stage, the evidence supports further research into PFI-3 and the BRG1 to CD47 pathway as a possible approach to artery plaque stability. Confidence is moderate for the mouse findings and the cell-based mechanism, since the results were consistent across several types of experiments. Confidence is low for any direct benefit in people, because no human testing has been reported. People with heart disease should not try to obtain or use PFI-3 on their own, and they should continue following guidance from their doctors, such as taking prescribed medicines, eating a heart-healthy diet, and getting regular checkups.

Heart disease researchers, drug developers, and clinicians who study plaque stability will find this work especially relevant. People with a family history of heart disease or high-risk plaque may also find it interesting as a sign of where future treatments may head. People who are looking for a quick fix or who are considering buying unregulated supplements should not apply these findings, since this research did not test any product sold to the public.

Compounds that show promise in mice usually take many years to reach people. Typically, a drug must go through safety testing, small early human trials, larger trials, and regulatory review before it becomes available. Even in the best case, it would likely be well over a decade before any treatment based on this pathway could be prescribed. In the meantime, the proven steps for protecting heart health, such as eating well, staying active, not smoking, and managing blood pressure and cholesterol, remain the most reliable choices.

Frequently Asked Questions

Can PFI-3 reduce plaque in arteries?

In a 2026 mouse study, PFI-3 reduced artery plaque area, dead-tissue core size, and immune cell buildup in high-fat-diet-fed mice. Researchers have not yet tested whether it works the same way in people, so its effects in humans remain unknown.

What is artery plaque and why does it matter?

Artery plaque is a buildup of fat, immune cells, and other material inside artery walls. When plaque becomes unstable, it can break open and form a blood clot, which is a common cause of heart attacks and strokes.

Does PFI-3 lower cholesterol?

In the mouse study, PFI-3 did not change blood fat or cholesterol levels. Its benefits appeared to come from effects on the artery wall itself, which suggests a different mechanism than many common cholesterol-lowering medicines.

Should I take PFI-3 to protect my heart?

No one should take PFI-3 based on this research. It has only been studied in mice and cells grown in labs, and its safety and effectiveness in people have not been established. Talk with a doctor about proven heart-health steps instead.

Want to Apply This Research?

  • Track the habits that are proven to support heart and artery health, such as daily steps, servings of vegetables, minutes of moderate exercise, and blood pressure readings if you have a home monitor. Log these weekly so you can see trends over time. Avoid logging PFI-3 or similar compounds, since no human use is recommended based on this research.
  • Set one small, achievable goal each week, such as adding one extra serving of vegetables to dinner or walking for 10 extra minutes after lunch. Use the app to check off each day you meet the goal. Small, steady changes are more likely to last than dramatic short-term efforts, and they support the same artery-health pathways that matter most right now.
  • Review your logged habits monthly and look for patterns, such as whether your activity or blood pressure readings are improving. Share the trends with your healthcare provider at routine visits. Watch for new research on PFI-3 and related compounds, but treat each new study as a reason to ask your doctor questions rather than as a reason to change your medicines or supplements.

This article summarizes early laboratory and mouse research and is for general information only. The findings have not been tested in people, and PFI-3 is not approved for treating heart disease or any other condition. Do not start, stop, or change any medicine, supplement, or treatment based on this article. Talk with a qualified healthcare provider about your individual heart health and risks.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: PFI-3 attenuates atherosclerotic plaque vulnerability and modulates a BRG1-SLUG-miR-193b-3p-CD47 axis in cultured vascular smooth muscle cells. , Life sciences (2026). PubMed 43035121 | DOI
Topics
PFI-3 artery plaque heart disease research CD47 BRG1 atherosclerosis plaque stability immune cell cleanup